<DOC>
	<DOCNO>NCT02336815</DOCNO>
	<brief_summary>This Phase 2b , single-arm , open-label , multicenter study selinexor 80 mg plus dexamethasone 20 mg ( Sd ) dose twice weekly four-week cycle , patient penta-refractory MM ( Parts 1 2 ) quad refractory MM ( Part 1 ) .</brief_summary>
	<brief_title>Selinexor Treatment Refractory Myeloma</brief_title>
	<detailed_description>This Phase 2b , single-arm , open-label , multicenter study selinexor 80 mg plus dexamethasone 20 mg ( Sd ) , dose twice weekly four-week cycle , patient MM previously treat lenalidomide , pomalidomide , bortezomib , carfilzomib , anti-CD38 monoclonal antibody ( mAb ) refractory prior treatment glucocorticoid , immunomodulatory agent ( IMiD ) , proteasome inhibitor ( PI ) , anti-CD38 mAb . This study consist two part : - Part 1 enrolled patient quad-refractory MM penta-refractory MM . - Part 2 enroll patient penta-refractory MM .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>Measurable MM base modify IMWG guideline . Defined least one following : 1 . Serum Mprotein ≥ 0.5 g/dL serum electrophoresis ( SPEP ) IgA myeloma , quantitative IgA 2 . Urinary Mprotein excretion ≥ 200 mg/24 hour 3 . Free Light Chain ( FLC ) ≥ 100 mg/L , provide FLC ratio abnormal 4 . If serum protein electrophoresis felt unreliable routine Mprotein measurement , quantitative Ig level nephelometry turbidimetry acceptable Must previously receive ≥ 3 antiMM regimen include : alkylating agent , lenalidomide , pomalidomide , bortezomib , carfilzomib , either daratumumab isatuximab , glucocorticoid . There upper limit number prior therapy provide inclusion/exclusion criterion meet . MM refractory previous treatment one glucocorticoid , parenteral PI ( i.e. , bortezomib and/or carfilzomib ) , IMiD ( i.e. , lenalidomide and/or pomalidomide ) , antiCD38 mAb ( i.e. , either daratumumab isatuximab ) . Refractory define ≤ 25 % response therapy , progression therapy progression within 60 day completion therapy . Active smolder MM . Active plasma cell leukemia . Documented systemic amyloid light chain amyloidosis . Active CNS MM .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>Karyopharm</keyword>
	<keyword>KPT-330</keyword>
	<keyword>Selinexor</keyword>
	<keyword>Refractory</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Carfilzomib</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Pomalidomide</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>STORM</keyword>
	<keyword>CD38</keyword>
</DOC>